Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.030
-0.040 (-3.74%)
At close: Mar 28, 2025, 4:00 PM
1.040
+0.010 (0.98%)
After-hours: Mar 28, 2025, 7:55 PM EDT
Werewolf Therapeutics Stock Forecast
HOWL's stock price has decreased by -83.78% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Werewolf Therapeutics stock have an average target of 9.00, with a low estimate of 4.00 and a high estimate of 15. The average target predicts an increase of 773.79% from the current stock price of 1.03.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Werewolf Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +676.70% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,356.31% | Mar 12, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $12 → $4 | Buy | Maintains | $12 → $4 | +288.35% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,356.31% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,356.31% | Jul 2, 2024 |
Financial Forecast
Revenue This Year
2.57M
from 1.89M
Increased by 36.45%
Revenue Next Year
10.20M
from 2.57M
Increased by 296.58%
EPS This Year
-1.76
from -1.63
EPS Next Year
-1.48
from -1.76
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.6M | 52.5M | 24.4M | ||
| Avg | 2.6M | 10.2M | 6.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 408.6% | 1,941.2% | 138.8% | ||
| Avg | 36.4% | 296.6% | -39.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.73 | -0.85 | -1.64 | ||
| Avg | -1.76 | -1.48 | -1.75 | ||
| Low | -1.80 | -2.20 | -1.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.